Clinical Scorecard: Identifying Defined Groups of Sequelae Following Coronavirus Disease 2019

At a Glance

Key Highlights

• PCC is a heterogeneous multisystemic condition with no single defining pathology, characterized by persistent symptoms beyond acute infection.
• Three distinct symptom-based phenotypes identified: sensory impairment, fatigue/cognitive difficulties, and difficulty breathing/exercise intolerance.
• Inflammatory biomarkers (CRP, interleukin 6) correlate with specific phenotypes, suggesting distinct biological patterns.

Guideline-Based Recommendations

Diagnosis

• Consider PCC diagnosis if symptoms persist ≥28 days (CDC) or ≥3 months (NICE, WHO) after initial SARS-CoV-2 infection.
• Use symptom-based phenotyping to classify patients into sensory, fatigue/cognitive, or respiratory clusters.
• Employ longitudinal symptom assessment at multiple time points (1, 3, 6, 9, 12 months) for monitoring.

Management

• Tailor management strategies based on phenotype and symptom severity.
• Address modifiable risk factors such as obesity and vaccination status.
• Recognize the multisystem involvement and provide multidisciplinary care.

Monitoring & Follow-up

• Use prospective surveys and symptom severity scales at defined intervals post-infection.
• Monitor inflammatory biomarkers where available to understand phenotype-specific pathology.
• Track symptom progression or resolution over time to guide prognosis.

Risks

• Obesity and hospitalization increase risk for breathing/exercise intolerance phenotype.
• Lack of vaccination is associated with sensory dysfunction phenotype.
• Persistent inflammation may contribute to symptom severity and chronicity.

Patient & Prescribing Data

Adults with confirmed SARS-CoV-2 infection exhibiting post-acute symptoms

Vaccination may reduce risk of certain PCC phenotypes; management should consider phenotype-specific symptom clusters and inflammatory profiles.

Clinical Best Practices

• Use data-driven, machine learning approaches to classify PCC phenotypes for targeted care.
• Implement longitudinal follow-up with symptom severity assessments at multiple time points.
• Incorporate inflammatory biomarker testing to aid understanding of pathophysiology.
• Recognize the heterogeneity of PCC and avoid a one-size-fits-all approach.
• Promote vaccination to potentially reduce risk of sensory dysfunction phenotype.

References

• CDC Post-COVID Conditions
• NICE COVID-19 Rapid Guideline: Managing the Long-term Effects of COVID-19
• WHO Clinical Case Definition of Post COVID-19 Condition
• Epsi et al. Major Article on PCC Phenotypes
• NIH RECOVER Initiative